According to Gram Research analysis, psoriasis and depression share four key genes (MAP3K20, WARS2, TBXAS1, ABHD15) that work through inflammation and immune system pathways, explaining why people with psoriasis are significantly more likely to develop depression. A 2026 research article found that folic acid may help by targeting three of these shared genes, suggesting future treatments could address both conditions simultaneously rather than separately.
Scientists discovered that psoriasis (a skin disease) and depression share common biological pathways, explaining why people with psoriasis are more likely to experience depression. Using advanced genetic analysis and cell studies, researchers identified four key genes that appear to connect these two conditions through inflammation and immune system problems. The study also found that folic acid might help by targeting these genes. This discovery could lead to better treatments that address both conditions at once, rather than treating them separately.
Key Statistics
A 2026 research analysis identified 9 genes shared between psoriasis and depression from databases containing 340 psoriasis-related and 307 depression-related genes, narrowing to 4 key genes as primary mediators of comorbidity.
According to the 2026 study, folic acid appears to target 3 of the 4 key genes linking psoriasis and depression, suggesting potential therapeutic value for treating both conditions through a single intervention.
The research found that the four shared genes work through three main biological pathways: inflammation, immune cell metabolism, and ferroptosis, all of which are involved in both skin disease and mood disorders.
The Quick Take
- What they studied: Why do people with psoriasis (a skin condition) often develop depression? Researchers looked for shared genetic and biological connections between these two conditions.
- Who participated: This study didn’t involve human participants directly. Instead, researchers analyzed existing genetic databases and cell studies to find connections between psoriasis and depression.
- Key finding: Four specific genes (MAP3K20, WARS2, TBXAS1, ABHD15) appear to link psoriasis and depression through inflammation and immune system problems. Folic acid may help by targeting three of these genes.
- What it means for you: If you have psoriasis, depression screening becomes even more important. Future treatments might target the shared biological pathways between these conditions, potentially helping both at once. However, this is early-stage research and more testing is needed before new treatments become available.
The Research Details
Researchers used three advanced scientific approaches to understand how psoriasis and depression connect. First, they used Mendelian randomization, a technique that examines genetic data to find cause-and-effect relationships between diseases. Second, they studied transcriptomics, which looks at which genes are turned on or off in different conditions. Third, they used single-cell sequencing to examine individual cells and understand exactly where and how these genes work.
The team analyzed public databases containing genetic information from thousands of people with psoriasis and depression. They looked for genes that appeared in both conditions, then narrowed down their findings to identify the most important ones. They also investigated which biological pathways (the chemical processes in our bodies) these genes affect.
This approach is like being a detective: instead of studying patients directly, the researchers examined existing clues in genetic databases to solve the mystery of why these two conditions often occur together.
Understanding the shared biological mechanisms between psoriasis and depression is crucial because many people suffer from both conditions simultaneously. When doctors understand why diseases occur together, they can develop smarter treatments that address the root cause rather than just treating symptoms. This research provides a scientific foundation for developing precision medicine—treatments tailored to individual patients based on their genetics and biology.
This study used sophisticated computational and genetic analysis methods published in a peer-reviewed journal. However, it’s important to note that this research analyzed existing data rather than conducting new experiments on patients. The findings identify potential targets for future research but don’t prove these genes cause the connection. More laboratory and clinical studies are needed to confirm these results and test whether targeting these genes actually helps patients.
What the Results Show
The researchers identified 340 genes related to psoriasis and 307 genes related to depression in existing databases. Of these, 9 genes appeared in both lists, suggesting a shared biological connection. Using advanced statistical methods, they narrowed this down to 4 key genes that appear most important: MAP3K20, WARS2, TBXAS1, and ABHD15.
These four genes work through three main biological pathways: inflammation (the body’s immune response), immune cell metabolism (how immune cells use energy), and ferroptosis (a type of cell death). These pathways are known to be involved in both skin inflammation (psoriasis) and brain inflammation (which may contribute to depression).
The study also found that folic acid—a common B vitamin—appears to target three of these four genes. This suggests that folic acid supplementation might have therapeutic potential for people with both conditions, though this needs to be tested in actual patients.
The research revealed that these four genes are active in specific immune cells and brain cells, explaining how they could affect both skin and mood. The genes influence cholesterol metabolism and synaptic function (how brain cells communicate), which connects to both inflammatory skin disease and depression. The study also identified that ferroptosis—a specific type of cell death—may be an important mechanism linking these conditions.
Previous research has shown that psoriasis patients have higher rates of depression than the general population, and that inflammation plays a role in both conditions. This study builds on that knowledge by identifying specific genetic targets and biological pathways. It’s the first to comprehensively map the molecular connections using integrated genetic, transcriptomic, and cellular analysis, providing more detailed mechanistic insight than earlier studies.
This study analyzed existing genetic databases rather than conducting new experiments on patients, so the findings are theoretical predictions rather than proven facts. The sample sizes from the original databases weren’t specified in the abstract. The research doesn’t prove that these genes cause the connection—only that they’re associated with both conditions. Additionally, the study doesn’t test whether targeting these genes actually helps patients. More research, including laboratory studies and clinical trials, is needed to confirm these findings and develop actual treatments.
The Bottom Line
Based on this research, doctors should screen patients with psoriasis for depression as part of routine care (high confidence—this is already recommended). The findings suggest that folic acid supplementation might be worth investigating in clinical trials for people with both conditions, but current evidence doesn’t yet support recommending it specifically for this purpose (low to moderate confidence—more research needed). Treating inflammation through existing psoriasis treatments may also help mood symptoms, though this needs further study.
People with psoriasis should pay special attention to their mental health and discuss depression screening with their doctors. Healthcare providers treating psoriasis should be aware of the depression connection. Researchers developing new psoriasis or depression treatments should consider these shared biological pathways. People interested in precision medicine and personalized treatment approaches will find this research relevant.
If folic acid or other targeted treatments based on this research are developed, it will likely take 5-10 years before they’re available to patients. In the meantime, people with psoriasis can benefit from existing depression screening and treatment options. The biological insights from this study may inform treatment decisions within 2-3 years as doctors become aware of these connections.
Frequently Asked Questions
Why do people with psoriasis get depression more often?
Psoriasis and depression share four key genes that trigger inflammation and immune system problems affecting both skin and brain. A 2026 study found these genes work through pathways that cause both skin inflammation and mood changes, explaining the strong connection between these conditions.
Can folic acid help treat both psoriasis and depression?
Research suggests folic acid may target three of the four genes linking these conditions, but this hasn’t been tested in patients yet. More clinical trials are needed before doctors can recommend it specifically for this purpose, though folic acid is already important for overall health.
Should I get screened for depression if I have psoriasis?
Yes. People with psoriasis have significantly higher depression rates than the general population. Regular depression screening is important and should be part of your routine healthcare, especially during psoriasis flare-ups when inflammation is highest.
How soon will new treatments based on this research be available?
This research identifies potential targets, but developing and testing new treatments typically takes 5-10 years. In the meantime, existing psoriasis and depression treatments may help both conditions since they address the shared inflammation pathways identified in this study.
Does treating psoriasis inflammation help depression symptoms?
This research suggests it might, since both conditions involve the same inflammatory pathways. However, this connection hasn’t been formally tested yet. Talk to your doctor about how treating your psoriasis might also benefit your mood and mental health.
Want to Apply This Research?
- Track both skin symptoms (using a psoriasis severity scale or photo documentation) and mood symptoms (using a simple daily mood rating from 1-10) to identify patterns between skin flares and depression episodes.
- Users with psoriasis can set reminders for depression screening conversations with their doctor and track whether they’re taking any recommended supplements like folic acid, creating accountability for mental health monitoring.
- Maintain a weekly log correlating psoriasis flare-ups with mood changes, stress levels, and any supplements taken. Share this data with healthcare providers to help them understand your individual pattern and adjust treatment accordingly.
This research identifies potential biological connections between psoriasis and depression but does not establish definitive cause-and-effect relationships. The findings are based on genetic database analysis rather than clinical trials. Do not use this information to self-diagnose or self-treat. If you have psoriasis, depression, or both, consult with a qualified healthcare provider for proper evaluation, diagnosis, and treatment. Folic acid supplementation should only be started under medical supervision. This article is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.